StreetAlpha.app
Home › Stocks › VTVT

vTv Therapeutics Inc. (VTVT)

$16.87
▼ −4.64%
LAST CLOSE · NOV 17

vTv Therapeutics develops oral medicines for metabolic and inflammatory diseases, led by a treatment being tested for type 1 diabetes. It last closed at $16.87 on Nov 17, down 4.64% on the day.

AI Auto Pilots
Is VTVT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$36.8M
+216600.0% vs a year ago
Net income
−$7.7M
−20.8% margin
Operating margin
−29.8%
−$11.0M operating income
Balance sheet
Cash & equivalents
$77.2M
At Sep 30
Shareholder equity
$69.7M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.0M$4.0MFY2021FY2022: $2.0M$2.0MFY2022FY2023: $0$0FY2023FY2024: $1.0M$1.0MFY2024FY2025: $0$0FY2025

From VTVT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated VTVT in the past 90 days.
Average 12-month target
No price targets on VTVT in the past 90 days.
Latest rating changes
HC Wainwright & Co.Maintained
Aug 6Buy$42
BTIGMaintained
Jul 16Buy$57
DateFirmActionRatingPrice target
Aug 6HC Wainwright & Co.MaintainedBuy$42
Jul 16BTIGMaintainedBuy$57
Loading…

Technical Analysis

VTVT · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 37% below its 20 day and 62% below its 50 day average. It is 94% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $16.71, and the nearest resistance the Pivot at $17.19.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 8.6%/day
Key levels
$44.0052 week high+160.8%
$32.69200 day average+93.8%
$30.18100 day average+78.9%
$27.4050 day average+62.4%
$27.01Swing high (Oct 29)+60.1%
$23.1020 day average+36.9%
$17.66Pivot R1+4.7%
$17.19Pivot+1.9%
$16.87Last close
$16.7152 week low−0.9%
$16.39Pivot S1−2.8%
Indicators
RSI (14)17.37Oversold below 30Oversold
MACD-2.67Below its signal lineBearish
Stochastic3.5Near the bottom of its rangeOversold
ADX (14)35.5Trending down
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-153.9Oversold below −100, overbought above 100Oversold
Rate of change−28.4%Change over 10 sessionsBearish
ATR (14)$1.45Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VTVT

What happened before

See how VTVT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow VTVT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How VTVT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in VTVT in the last 90 days.

Loading…

See today’s whale options flow across the market →

VTVT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼17 buying vs 22 selling
  • ▲Shares held by funds +8.5%
  • ▼Funds holding -7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding3845−15.6%
In funds' top 1000–
Held by funds–––
New / increased5 / 1217 / 6−26.1%
Reduced / sold out10 / 128 / 6+57.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VTVT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VTVT is in one of them and how their past VTVT trades turned out.

VTVT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VTVT in an article yet. Here's the latest on the wider market.

About vTv Therapeutics

vTv Therapeutics is a biopharmaceutical company based in High Point, North Carolina. It develops oral medicines for metabolic and inflammatory diseases. Its main product candidate, cadisegliatin, is being tested as a medicine taken by mouth alongside insulin for people with type 1 diabetes, a condition in which the body stops producing insulin. The company also works with partners on its other drug candidates.

Headquarters
High Point, NC